


**Product Name** : PF-07817883  
**Cat. No.** : PC-22258  
**CAS No.** : 2755812-39-4  
**Molecular Formula** : C<sub>21</sub>H<sub>30</sub>F<sub>3</sub>N<sub>5</sub>O<sub>5</sub>  
**Molecular Weight** : 489.50  
**Target** : SARS-CoV-2 Inhibitors  
**Solubility** : 10 mM in DMSO



CAS: 2755812-39-4

## Biological Activity

PF-07817883 (Ibuzatrelvir) is a second-generation, orally bioavailable, SARS-CoV-2 main protease (Mpro) with Ki value of 2.48 nM, EC50 of 180 nM for inhibition of SARS-CoV-2 induced cytopathic effect (CPE).

PF-07817883 (Ibuzatrelvir) shows improved metabolic stability versus nirmatrelvir, the antiviral component of the ritonavir-boosted therapy Paxlovid.

PF-07817883 (Ibuzatrelvir) inhibits the SARS-CoV-1 Mpro (IC50 = 18 nM) and MERS Mpro (IC50 = 930 nM) activity, respectively, but has a much smaller disparity in the cell-based antiviral assays (SARS-CoV-1 EC50 = 157 nM and MERS EC50 = 158 nM).

PF-07817883 (Ibuzatrelvir) potently inhibits SARS-CoV-2 viral replication with EC50 and EC90 values of 34 nM and 70 nM respectively in Vero76 cells.

PF-07817883 (Ibuzatrelvir) also demonstrated oral efficacy in a mouse-adapted SARS-CoV-2 model at plasma concentrations equivalent to nirmatrelvir.

## References

Allerton CMN, et al. J Med Chem. 2024 Apr 30. doi: 10.1021/acs.jmedchem.3c02469.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com